FDA approves first CAR-T cell therapy for multiple myeloma
Bio Pharma Dive
MARCH 27, 2021
Approval of Bristol Myers Squibb and Bluebird bio's Abecma expands use of CAR-T treatment beyond leukemia and lymphoma.
Sat.Mar 27, 2021
362 
New patent expiration for R-pharm Us drug IXEMPRA KIT
Drug Patent Watch
MARCH 27, 2021
Annual Drug Patent Expirations for IXEMPRA+KIT Ixempra Kit is a drug marketed by R-pharm Us Llc and is included in one NDA. It is available from one supplier. There are…. The post New patent expiration for R-pharm Us drug IXEMPRA KIT appeared first on DrugPatentWatch - Make Better Decisions.
Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Clearing of woody weeds in Baringo County, Kenya, may yield major livelihood benefits
Scienmag
MARCH 27, 2021
A new study suggests that clearing the invasive woody weed Prosopis julifora and grassland restoration in Baringo County, Kenya, may have significant financial benefits for local stakeholders and contribute to climate change mitigation. Credit: CABI A new study suggests that clearing the invasive woody weed Prosopis julifora and grassland restoration in Baringo County, Kenya, may […].
Gilead Sciences Appoints Flavius Martin, MD as Executive Vice President, Research
The Pharma Data
MARCH 27, 2021
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Flavius Martin, MD will join the company as Executive Vice President, Research, and will become a member of the company’s senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O’Day. Dr. Martin will assume responsibility for Gilead’s research organization effective April 12, 2021.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
???????PAION RECEIVES EUROPEAN COMMISSION APPROVAL OF BYFAVO(R) (REMIMAZOLAM) FOR PROCEDURAL SEDATION
BioTech 365
MARCH 27, 2021
PAION AG / Key word(s): Regulatory Approval ???????PAION RECEIVES EUROPEAN COMMISSION APPROVAL OF BYFAVO(R) (REMIMAZOLAM) FOR PROCEDURAL SEDATION 27-March-2021 / 13:43 CET/CEST Disclosure of an inside information acc.
Resolutions from the Annual General Meeting of Novo Nordisk A/S
The Pharma Data
MARCH 27, 2021
Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, chair of the of Board of Directors stated: “In 2020, Novo Nordisk showed agility and resilience in very challenging times, and the COVID-19 pandemic has underscored the importance of continued innovation and relevance of businesses in times of crisis.
Saxenda® is expanded for the treatment of obesity in adolescents aged 12–17 years
The Pharma Data
MARCH 27, 2021
Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda ® is expanded for the treatment of obesity in adolescents aged 12–17 years. 1. Over the last 20 years, the global prevalence of obesity in children and adolescents has doubled from 1 in 10 to 1 in 5, 2,3 and now more than 124 million children and adolescents live with obesity globally. 4 Adolescents with obesity are more
Let's personalize your content